Associate Professor, Pediatrics, Perelman School of Medicine
Pediatric Hematology & Oncology
Dr. Michael D. Hogarty, MD
|
|
Give Review
Dr. Michael D. Hogarty is an expert in the field of Pediatric Hematology & Oncology. He studied medicine at Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a one of the best medicals schools. Columbia University College of Physicians & Surgeons is ranked 8/52 in Research/PrimaryCare. Michael D. Hogarty is a published MD. He has 64 publications published. The most current publication "Wild-type sequence of MYCN in neuroblastoma cell lines."
Publications
- Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma.
- EGFR signaling defines Mcl(-)1 survival dependency in neuroblastoma.
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma.
- Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group.
- Detection of circulating tumor DNA in early- and late-stage human Malignancies.
- Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Onco...
- The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737.
- Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
- The genetic landscape of high-risk neuroblastoma.
- Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood Cancer neuroblastoma.
- ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation.
- miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.
- IL-17A in LCH: Systemic Biomarker, Local Factor, or None of the Above?
- Pediatric horner syndrome.
- Langerhans cell histiocytosis of the uvea with neovascular glaucoma: diagnosis by fine-needle aspiration biopsy and management with intraocular bevacizumab and brachyt...
- Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
- Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.
- Influence of neuroblastoma stage on serum-based detection of MYCN amplification.
- Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
- Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
- ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
- Isolation and characterization of a novel Francisella sp. from human cerebrospinal fluid and blood.
- Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma.
- Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions.
- Cutaneous metastatic chordoma with concomitant tuberous sclerosis.
- Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
- ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
- No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.
- Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.
- Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
- BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.
- Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group.
- MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
- Analysis of genomic imprinting at 1p35-36 in neuroblastoma.
- Detailed molecular analysis of 1p36 in neuroblastoma.
- Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
- Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.
- Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
- BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines with MYCN amplification.
- Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
- Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13.
- Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas.
- Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Ca...
- Longitudinal evaluation of cardiopulmonary performance during exercise after bone marrow transplantation in children.
- Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
- Wild-type sequence of MYCN in neuroblastoma cell lines.
- Mononucleotide repeat instability is infrequent in neuroblastoma.
- Biology and genetics of human neuroblastomas.
- Pulmonary Mycobacterium gordonae infection in a two-year-old child: case report.
- Health care policy, values, and nursing.
- N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells.
- Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
- BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.
- The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.
- Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.
- Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.
- Neuroblastoma.
- Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children''s Oncolog...
- Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
- Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in Cancer.
- Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein.
- Mutations in PIK3CA are infrequent in neuroblastoma.
- PI3King on MYCN to Improve Neuroblastoma Therapeutics.
Schools
Columbia University College of Physicians And Surgeons
Children39s Hospital Philadelphia
McGaw Med Center Of Northwestern
Conditions Treated
- Anemia
- ENT Cancer
- Liver Cancer
- Lung Cancer
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Education
-
Children's Hospital of Philadelphia -
McGaw Medical Center of Northwestern University -
Columbia University College of Physicians & Surgeons
Helpful Reviews
Similar Doctors
|
|
Dr. Leslie J. Raffini, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Deepti A. Raybagkar, MB
This Doctor is OpenDoctor Recommended.
|
|
Dr. Norma Lerner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Haewon C. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carly R. Varela, MD
This Doctor is OpenDoctor Recommended.
|